Top Antibody CMO Supporting the Biologic Drug Developers

Top Antibody CMO Supporting the Biologic Drug Developers

The antibody contract manufacturing market is witnessing robust growth, propelled by several key drivers, including demand for biologics, rising prevalence of chronic diseases and the trend towards personalized medicine. We analyzed over 125 antibody CMO that are engaged in offering services for antibodies manufacturing. In this article, discover seven top antibody contract manufacturers and their capabilities in the overall antibody manufacturing market.

Interested in exploring all 125+ Antibody CMO and their recent initiatives?

Antibodies constitute one of the fastest growing drug classes amongst the diverse range of biologics. Over the years, there has been evolution of concepts and methods, which have facilitated several innovative advances in the development and manufacturing of increasingly complex and efficacious antibody-based therapeutics. Despite the fact that biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, these therapeutic products are generally known to be associated with high costs of development and complex manufacturing protocols. As such the biologics contract manufacturing market has seen a steady growth driven by the many benefits offered by these players.
In order to help antibody developers to keep pace with the growing demand for specialized manufacturing services, there are a number of contract manufacturing organizations (CMOs), offering services for the development and production of antibodies. The antibody contract manufacturing market is characterized by the presence of both niche specialty companies, focused on early-stage development and production (preclinical and / or clinical scales), and one-stop-shop antibody CMO that have, over time, acquired an extensive range of capabilities in order to cater to all product development and commercialization requirements of their clients.
Roots Analysis has conducted an exhaustive study on Antibody Contract Manufacturing Market featuring the current market landscape and future opportunity for the companies engaged in offering services for antibody manufacturing, over a span of 11 years.

Table of Contents

Below, we have listed (in alphabetical order), the top seven Antibody CMO:
1.    AGC Biologics
2.    Emergent BioSolutions
3.    Fujifilm Diosynth Biotechnologies
4.    KBI Biopharma
5.    Lonza
6.    Samsung Biologics
7.    Thermo Fisher Scientific

Discover Below the Details on 7 Top Antibody CMO

Let us deep dive to understand the activity of the 7 top antibody contract manufacturers offering several services to support manufacturing of antibody-based therapeutics. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

AGC Biologics is Investing in Expansion of Global Capacity for Antibody Manufacturing

1. AGC Biologics
AGC Biologics is a well-established CDMO, focused on the development and manufacturing of biopharmaceuticals. The firm has experience in contract process development and manufacturing, with close to 200 biological projects for preclinical through commercial approval. In addition, the firm provides uniquely customized services for scale-up and manufacturing of protein therapeutics.

AGC Biologics: Company Overview

Particulars	Specifications
Company Logo
Year of Establisment	2018
Number of Employees	1,001-5,000
Headquarter	US

The company offers a wide range of services from cell line development to antibody drug development and protein expression, using mammalian and microbial production systems. In June 2024, AGC Biologics announced the completion of Copenhagen campus expansion, doubling single-use mammalian bioreactor capacity at site. Additionally, the antibody CMO is also investing in a new facility in Yokohama, Japan and In April 2024, collaborated with Cytiva for its FlexFactory platform, a modular construction platform, to support mRNA and antibody manufacturing.

Recent Developments:
In June 2024, Essential Pharma signed an agreement with AGC Biologics for process development, scale-up and manufacturing of its clinical stage humanized monoclonal antibody, Hu14.18.

In August 2023, the company entered into process development and manufacturing agreement with Asahi Kasei Pharma to produce clinical drug substances for antibody-based therapies at Seattle manufacturing site.

Further details on recent initiatives taken by AGC Biologics and other antibody CMO have been provided in detail in the report.

Emergent BioSolutions, is Amongst the Antibody CMO with Largest Installed Single Use Bioreactor

2. Emergent BioSolutions

Emergent BioSolutions is a life sciences company dedicated towards providing specialty products for civilian and military populations, with an aim to address public health and national security threats (collectively public health threats (PHTs)). The company offers a wide range of contract manufacturing services for both bulk drug substances and sterile injectable drug products.

Emergent BioSolutions: Company Details

Particulars	Specifications
Company Logo
Year of Establisment	1998
Number of Employees	1,001-5,000
Headquarter	US

The company claims to have eight manufacturing facilities focused on antibody manufacturing in different countries across the globe. The company installed a 4,000 Lt single-use bioreactor from ABEC at its Baltimore, Maryland facility in 2017. This is amongst the largest single use bioreactors available in the market.

Recent Developments:
In October 2022, the company entered into manufacturing service agreement with SAB Biotherapeutic with an aim to produce SAB’s fully human polyclonal antibody products.

Further details on recent initiatives taken by Emergent BioSolutions and other antibody CMO have been provided in detail in the report.

Fujifilm is Working on Constructing Identical Biologic Manufacturing Facilities Across the Globe to Allow Easy Transition for Clients

3. Fujifilm Diosynth Biotechnologies

Fujifilm Diosynth Biotechnologies’s primary focus is to integrate expertise in cell culture, microbial fermentation, and cell and gene therapy with top-tier cGMP manufacturing facilities, with the goal of advancing the pharmaceutical industry in coming future. Operating as a CDMO entity, it strives to provide technical leadership in these areas. With a track record spanning over three decades, the company has been assisting its clients with the development and production of recombinant proteins, viral vaccines, and gene therapies.

Fujifilm Diosynth Biotechnologies: Company Overview

Particulars	Specifications
Company Logo
Year of Establisment	2011
Number of Employees	1,001-5,000
Headquarter	US

The company is investing funds towards its cloning concept, KojoXTM under which it plans to have identical large-scale facilities in the US and Europe, to allow shorter lead times and smooth compliance with regulations its clients across global locations. Currently, their Denmark site is the main production site for antibody manufacturing. In April 2024, the company announced an investment of $1.2 billion for addition of 8 x 20,000 Lt mammalian cell culture bioreactors at its Holly Springs, North Carolina facility by 2028.

Recent Developments:

• In March 2024, the company announced the extension of its manufacturing agreement with Argenx with an aim to provide drug product and finished goods services for Efgartigimod, a monoclonal antibody fragment targeting neonatal Fc receptor, in patients suffering from autoimmune disease.
• In June 2023, Fujifilm launched a commercial office in Tokyo to provide enhanced customer service for contract development and manufacturing services for biologics and advanced therapies.

Further details on recent initiatives taken by Fujifilm Diosynth Biotechnologies and other antibody CMO have been provided in detail in the report.

KBI Biopharma Launched SUREmAb for Accelerated Antibody Development and Manufacturing

4. KBI Biopharma

KBI Biopharma claims to be a customer oriented CDMO aiming to advance its position in the biopharmaceutical sector. The company is focused on the development of advanced biological products using innovative technologies. It offers its expertise in process development and cGMP manufacturing programs for a broad range of recombinant proteins. The company offers its antibody manufacturing services through GMP, to the biopharmaceutical industry for the manufacturing of monoclonal antibodies. The firms claim that the aforementioned set of services help in reducing the overall time to market and total cost of manufacturing.

KBI Biopharma: Company Overview

Particulars	Specifications
Company Logo
Year of Establisment	1966
Number of Employees	1,001-5,000
Headquarter	US

In September 2023, KBI launched SUREmAb, built on the robustness Of it’s SUREtechnology platform. The company aims to optimize monoclonal antibody development and manufacturing and make the process cost-efficient.

Recent Developments:

In December 2023, the company appointed Tony Fraij  as Chief Operating Officer; Shaguna Seth  as Chief of Staff and Global PMO Leader; Katie Edgar  as Senior Vice President of Corporate Strategy and Alliance Management; and Sarah Wakefield  as Senior Vice President, Corporate Communications. In the coming years, the firm is likely to recruit other eminent personalities to its management team in order to augment the thought leadership to pave way for future growth.
Further details on recent initiatives taken by KBI Biopharma and other antibody CMO have been provided in detail in the report.

Lonza is a Leading Antibody CMO That Has Supported Major Biopharmaceutical Companies

5. Lonza

Lonza claims to be one of the leading contract manufacturers in the world, with expertise in monoclonal antibodies and affiliated products as well. It offers a wide range of products and services to the pharmaceutical, healthcare and life science industries, including academic players and government research institutes. In addition to this, it offers services for mammalian and microbial expression systems. It also offers high-potential active pharmaceutical ingredients, cell and gene therapy capabilities, oral drug product development services, cell-culture modeling, genome editing, endotoxin products, and research media and testing products.

Lonza: Company Overview

Particulars	Specifications
Company Logo
Year of Establisment	1847
Number of Employees	10,001+
Headquarter	Switzerland

Recent Developments:

• In April 2024, the company announced its service agreement with Acumen Pharmaceuticals for clinical and commercial supply of sabirnetug (ACU193), an antibody in phase I clinical trials for the treatment of Alzheimer’s Disease. The production will take place at Lonza’s Portsmouth facility.
• In June 2022, Lonza entered into a collaboration with Pierre Fabre for manufacturing of WO180 antibody drug product.

Further details on recent initiatives taken by Lonza and other antibody CMO have been provided in detail in the report.

Samsung Biologics, with Monoclonal Antibody Manufacturing Capacity of Over 360,000 Liters is a Leading Antibody CMO in Asia Pacific

6. Samsung Biologics
Samsung Biologics is a comprehensive contract development and manufacturing organization that provides integrated services covering the entire biopharmaceutical production process, from cell line development to final aseptic fill/finish, along with laboratory testing services at all stages. The company's facilities adhere to current Good Manufacturing Practice standards and feature bioreactors of various scales to cater to diverse client requirements. In order to enhance operational efficiency and meet the increasing demands of biomanufacturing, Samsung Biologics has introduced Plant 5 at Songdo, which will further solidify its position by taking its total biomanufacturing capacity to 784KL upon its completion in 2025.

Samsung Biologics: Company Overview

Particulars	Specifications
Company Logo
Year of Establisment	2011
Number of Employees	201-500
Headquarter	South Korea

Recent Developments:

• In February 2024, the company collaborated with LegoChem Biosciences with an aim to develop and manufacture antibodies for ADC candidates.
• In September 2023, Samsung Biologics entered into a strategic agreement with Bristol Myers Squibb in order to manufacture antibody cancer drug substance.

Further details on recent initiatives taken by Samsung Biologics and other antibody CMO have been provided in detail in the report.

Thermo Fisher Scientific’s Acquisition of Patheon in 2017 Provided it With the Biologic Manufacturing Service Capabilities

7. Thermo Fisher Scientific

Thermo Fisher Scientific offers a comprehensive range of analytical instruments, life sciences solutions, specialty diagnostics, and laboratory services. Their diverse product lineup encompasses laboratory supplies, equipment, and instruments, along with clinical and diagnostics tools, chromatography and mass spectrometry devices, chemicals, cell culture materials, protein and cell analysis tools, and molecular biology and nucleic acid analysis products. These products and services cater to a wide array of industries including industrial and applied sciences, biotechnology, pharmaceuticals, healthcare, food & beverage, and forensics.

Thermo Fisher Scientific: Company Overview

Particulars	Specifications
Company Logo
Year of Establisment	1956
Number of Employees	10,000+
Headquarter	US

According to the company website, 70% of the projects that Patheon worked on during the period 2018-2022 were for monoclonal antibodies, showing its experience in the field.

Recent Developments:

• In March 2024, the company presented at TD Cowen 44th Annual Health Care Conference held in Boston. The firm is anticipated to continue to participate in more of such events in order to gain more visibility in the overall healthcare domain.
• In February 2024, Thermo Fisher Scientific collaborated with Elektrofi to strengthen manufacturing capabilities for future clinical supply of various drug classes including monoclonal antibodies and therapeutic proteins.

Further details on recent initiatives taken by Thermo Fisher Scientific and other antibody CMO have been provided in detail in the report.

What About Other Antibody CMO Around the World?

The above presentation features seven top antibody contract manufacturers selected from a pool of over 125 players that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources

1.    https://www.accesswire.com/871292/agc-biologics-completes-copenhagen-campus-expansion-doubling-single-use-mammalian-bioreactor-capacity-at-site
2.    https://www.biopharminternational.com/view/agc-biologics-partners-with-asahi-kasei-on-clinical-antibody-project
3.    https://www.emergentbiosolutions.com/news/sab-biotherapeutics-announces-exclusive-manufacturing-partnership-with-emergent-biosolutions/
4.    https://fujifilmdiosynth.com/about/news/fujifilm-to-enhance-commercial-presence-in-asia-for-biologics-and-advanced-therapies-contract-services/
5.    https://fujifilmdiosynth.com/about/news/fujifilm-diosynth-biotechnologies-expands-manufacturing-agreement-with-argenx-for-efgartigimod-a-mab-for-the-treatment-of-severe-autoimmune-diseases/
6.    https://www.kbibiopharma.com/news/kbi-expands-global-portfolio-with-launch-of-suremab
7.    https://leadiq.com/c/kbi-biopharma/5a1d8a012400002400635b39
8.    https://www.pharmtech.com/view/pierre-fabre-and-lonza-enter-manufacturing-agreement
9.    https://www.prnewswire.com/news-releases/samsung-biologics-announces-expanded-strategic-agreement-with-bristol-myers-squibb-to-manufacture-an-antibody-cancer-drug-substance-301929880.html
10.  https://www.prnewswire.com/news-releases/samsung-biologics-partners-with-legochem-biosciences-for-adc-development-and-manufacturing-302055657.html